Literature DB >> 1600780

Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome.

J M Reich1, R E Johnson.   

Abstract

BACKGROUND: Pulmonary disease due to Mycobacterium avium complex (MAC-PD) radiographically resembles that due to tuberculosis; it preferentially affects elderly white men with predisposing pulmonary disorders (PDPD).
METHODS: Twenty-nine patients with MAC-PD were identified from a community-based population, and the medical records and chest roentgenograms (CRs) of six with a previously undescribed pattern of MAC-PD were reviewed. The distinctive clinical and demographic features of these six patients were identified and summarized.
RESULTS: All were women who tended to be elderly. None had clinically evident PDPD. The dependent portion of the lingula or its counterpart, the middle lobe, was initially affected. Hilar adenopathy, volume loss, and cavitary disease were uniformly absent.
CONCLUSIONS: To account for the distinctive features of this syndrome, we offer the hypothesis that habitual voluntary suppression of cough may have led to the development of nonspecific inflammatory processes in these poorly draining lung regions, upon which MAC-PD engrafted. We offer the term, Lady Windermere's syndrome, to describe this pattern among elderly women and to suggest that their fastidiousness may be its root cause.

Entities:  

Mesh:

Year:  1992        PMID: 1600780     DOI: 10.1378/chest.101.6.1605

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  67 in total

Review 1.  Nontuberculous mycobacteria and the lung: from suspicion to treatment.

Authors:  Emmet E McGrath; Zoe Blades; Josie McCabe; Hannah Jarry; Paul B Anderson
Journal:  Lung       Date:  2010-04-09       Impact factor: 2.584

Review 2.  Management of nontuberculous mycobacterial infection in the elderly.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Golnaz Ebrahimi; Stefano Aliberti; Joseph O Falkinham
Journal:  Eur J Intern Med       Date:  2014-03-29       Impact factor: 4.487

Review 3.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 4.  Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.

Authors:  Patrick A Flume; James D Chalmers; Kenneth N Olivier
Journal:  Lancet       Date:  2018-09-08       Impact factor: 79.321

5.  Lady Windermere Dissected: More Form Than Fastidious.

Authors:  Kenneth N Olivier
Journal:  Ann Am Thorac Soc       Date:  2016-10

6.  High-resolution CT of nontuberculous mycobacteria pulmonary infection in immunocompetent, non-HIV-positive patients.

Authors:  R Polverosi; A Guarise; E Balestro; A Carloni; G Dalpiaz; B Feragalli
Journal:  Radiol Med       Date:  2009-12-14       Impact factor: 3.469

Review 7.  Diagnosis and treatment of nontuberculous mycobacterial pulmonary diseases: a Korean perspective.

Authors:  Won-Jung Koh; O Jung Kwon; Kyung Soo Lee
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

8.  Thin-section CT findings of nontuberculous mycobacterial pulmonary diseases: comparison between Mycobacterium avium-intracellulare complex and Mycobacterium abscessus infection.

Authors:  Myung Jin Chung; Kyung Soo Lee; Won-Jung Koh; Ju Hyun Lee; Tae Sung Kim; O Jung Kwon; Seonwoo Kim
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

9.  HRCT in detection of pulmonary infections from nontuberculous mycobacteria: personal experience.

Authors:  I Ferrara; S Cappabianca; L Brunese; T Valente; E Muto; R Muto; A Rotondo
Journal:  Radiol Med       Date:  2009-03-11       Impact factor: 3.469

Review 10.  Nontuberculous mycobacterial pulmonary diseases in immunocompetent patients.

Authors:  Won-Jung Koh; O Jung Kwon; Kyung Soo Lee
Journal:  Korean J Radiol       Date:  2002 Jul-Sep       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.